Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Chris Shibutani is an analyst at Goldman Sachs. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 06/11/2024
| Buy Now | Get Alert | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 05/28/2024 | ERAS | Buy Now | Erasca | $2.22 | 80.18% | $7 → $4 | Maintains | Buy | Get Alert |
| 05/13/2024 | RVNC | Buy Now | Revance Therapeutics | $2.94 | 172.11% | $9 → $8 | Maintains | Neutral | Get Alert |
| 05/06/2024 | OGN | Buy Now | Organon | $20.45 | -2.2% | $18 → $20 | Maintains | Neutral | Get Alert |
| 05/03/2024 | UTHR | Buy Now | United Therapeutics | $275.76 | -12.97% | $218 → $240 | Maintains | Neutral | Get Alert |
| 05/03/2024 | OGN | Buy Now | Organon | $20.45 | -2.2% | $18 → $20 | Maintains | Neutral | Get Alert |
| 04/11/2024 | LLY | Buy Now | Eli Lilly and Co | $864.00 | -16.32% | $650 → $723 | Maintains | Neutral | Get Alert |
| 04/02/2024 | ERAS | Buy Now | Erasca | $2.22 | 215.32% | $6 → $7 | Maintains | Buy | Get Alert |
| 03/11/2024 | AMLX | Buy Now | Amylyx Pharma | $1.74 | 129.89% | $40 → $4 | Downgrade | Buy → Neutral | Get Alert |
| 03/01/2024 | SDGR | Buy Now | Schrodinger | $21.00 | 23.81% | $29 → $26 | Maintains | Neutral | Get Alert |
| 03/01/2024 | RVNC | Buy Now | Revance Therapeutics | $2.94 | 206.12% | $8 → $9 | Maintains | Neutral | Get Alert |
| 02/28/2024 | BNTX | Buy Now | BioNTech | $98.90 | 1.11% | $113 → $100 | Maintains | Neutral | Get Alert |
| 02/20/2024 | RPRX | Buy Now | Royalty Pharma | $27.42 | 82.35% | $56 → $50 | Maintains | Buy | Get Alert |
| 02/20/2024 | OGN | Buy Now | Organon | $20.45 | -11.98% | $16 → $18 | Maintains | Neutral | Get Alert |
| 02/12/2024 | UTHR | Buy Now | United Therapeutics | $275.76 | -22.03% | $213 → $215 | Upgrade | Sell → Neutral | Get Alert |
| 01/25/2024 | NBIX | Buy Now | Neurocrine Biosciences | $133.15 | 14.91% | $134 → $153 | Maintains | Buy | Get Alert |
| 01/09/2024 | RVNC | Buy Now | Revance Therapeutics | $2.94 | 172.11% | $30 → $8 | Downgrade | Buy → Neutral | Get Alert |
| 12/11/2023 | ABBV | Buy Now | AbbVie | $167.70 | 3.16% | → $173 | Upgrade | Neutral → Buy | Get Alert |
| 11/10/2023 | AMLX | Buy Now | Amylyx Pharma | $1.74 | 2198.85% | $46 → $40 | Maintains | Buy | Get Alert |
| 11/09/2023 | NKTR | Buy Now | Nektar Therapeutics | $1.22 | — | — | Upgrade | Market Perform → Outperform | Get Alert |
| 11/03/2023 | MCRB | Buy Now | Seres Therapeutics | $0.77 | 62.13% | $4 → $1.25 | Maintains | Sell | Get Alert |
| 11/03/2023 | OGN | Buy Now | Organon | $20.45 | -21.76% | $33 → $16 | Downgrade | Buy → Neutral | Get Alert |
| 10/30/2023 | BMY | Buy Now | Bristol-Myers Squibb | $42.90 | 60.84% | $81 → $69 | Maintains | Buy | Get Alert |
| 10/11/2023 | SNDX | Buy Now | Syndax Pharmaceuticals | $19.71 | 52.21% | → $30 | Initiates | → Buy | Get Alert |
| 09/21/2023 | RVNC | Buy Now | Revance Therapeutics | $2.94 | 1022.45% | $38 → $33 | Maintains | Buy | Get Alert |
| 08/10/2023 | LLY | Buy Now | Eli Lilly | $864.00 | -45.6% | $385 → $470 | Maintains | Neutral | Get Alert |
| 08/09/2023 | LLY | Buy Now | Eli Lilly | $864.00 | -45.6% | $385 → $470 | Maintains | Neutral | Get Alert |
| 07/24/2023 | AMLX | Buy Now | Amylyx Pharma | $1.74 | 2716.09% | $45 → $49 | Upgrade | Neutral → Buy | Get Alert |
| 05/16/2023 | ERAS | Buy Now | Erasca | $2.22 | 305.41% | $10 → $9 | Maintains | Buy | Get Alert |
| 05/10/2023 | EQRX | Buy Now | EQRx | — | — | $5 → $3 | Maintains | Neutral | Get Alert |
| 03/28/2023 | BNTX | Buy Now | BioNTech | $98.90 | 41.56% | $156 → $140 | Maintains | Neutral | Get Alert |
